Funding life sciences
L1 Health partners with entrepreneurs and industry executives to invest in long-term, global trends that transform healthcare. We look for acquisition and partnership opportunities that position us at critical points in the healthcare value chain. We favour platforms with strategic long-term value creation potential.
Patient Capital with Operator Mindset
With over $3bn in evergreen capital at its disposal, L1 Health has the ability to underwrite hold periods longer than a typical private equity fund. This allows us to focus on platforms that take time to build, and to invest throughout economic cycles.
Consistent with LetterOne’s entrepreneurial heritage, L1 Health approaches investments with an operator mindset. We understand the time and investment required to build industry leading and transformative platforms. We also appreciate that rigorous operational focus is required to develop market momentum. Therefore, we partner with outstanding operating executives and give them the freedom and support they need to realize each platform’s long-term potential.
In addition, we have the flexibility to tailor our approach to each opportunity – from majority control positions to initial minority stakes, from private transactions to investments in public equities and structured products, from equity-heavy to leveraged situations, and from start-up companies to industry leaders. Without a fixed time horizon for exit, we can adapt capital structures over time consistent with the needs of the opportunity.
Consistent with LetterOne's entrepreneurial heritage, L1 Health approaches investments with an operator mindset.Stefan LinnManaging Partner, L1 Health
First-Class Investment Team
The L1 Health team has extensive operating experience, as well as specialized expertise in private equity, banking, financial operations, policy, governance, strategy and M&A in the healthcare industry in the U.S. and Europe.
The L1 Health team is composed of internationally respected senior operating executives and investment professionals and includes Dr Franz Humer, former CEO and Chairman of Roche Holding Ltd, and Rolf Classon, former CEO and President of Bayer Healthcare LLC.
For more information on our team, click here.
Our Investment Team comprises operating executives and investment professionals from the healthcare industry with extensive experience in leading, advising and financing health organisations across healthcare. The Investment Team works closely together with entrepreneurs and management teams to develop investment strategies, originate and execute investments, and support our portfolio companies.
Consistent with its mission to invest in transformative platforms backed by long-term industry trends, in October 2019 L1 Health acquired Destination Pet and launched a new animal health and wellness platform in the U.S. and Europe. Destination Pet is a leader in pet health care services and a trusted high-quality pet care and vet services provider. In 2019 L1 also invested in K2 HealthVentures (K2HV), which is a start-up venture, providing life sciences companies at the venture and growth stages with innovative financing solutions.
For more information on our portfolio companies, click here.